DESKTOP III / ENGOT-ov20
Operating again at first relapse, in carefully selected women, added about seven months of life.
OS 53.7 vs 46.0 months (HR 0.75; NEJM 2021); the benefit was concentrated in patients with complete resection (61.9 months). Contradicted the negative GOG-0213 surgery arm, with patient selection (AGO score) the likely explanation.
- Median 53.7 vs 46 months with Surgery + chemotherapy compared with Chemotherapy alone; about 7.7 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 25 percent lower chance of the event at any given time (hazard ratio 0.75, likely range 0.59 to 0.96).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: First platinum-sensitive relapse with a positive AGO score: secondary cytoreductive surgery + chemotherapy vs chemotherapy alone. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
407 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Surgery + chemotherapy | 206 | 53.7 months | 0.75 (0.59–0.96) | — | link |
| Chemotherapy alone | 201 | 46 months |
Pages like this
not linked directly; found by shared links- InstitutionChris O'Brien Lifehouse
Shares Robotic & minimally invasive surgery, Ovarian cancer.
- InstitutionPeking Union Medical College Hospital
Shares Robotic & minimally invasive surgery, Ovarian cancer.
- InstitutionIRCCS Regina Elena National Cancer Institute
Shares Robotic & minimally invasive surgery, Ovarian cancer.
- InstitutionEuropean Society of Gynaecological Oncology
Shares Robotic & minimally invasive surgery, Ovarian cancer.
- InstitutionSociety of Gynecologic Oncology
Shares Robotic & minimally invasive surgery, Ovarian cancer.